OncoMatch/Clinical Trials/NCT04900818
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Is NCT04900818 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including TJ033721 (givastomig) and TJ033721 (givastomig) , nivolumab, chemotherapy for solid tumor.
Treatment: TJ033721 (givastomig) · TJ033721 (givastomig) , nivolumab, chemotherapy · TJ033721 (givastomig), chemotherapy · TJ033721 (givastomig), durvalumab, chemotherapy — This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Gastric Cancer
Esophageal Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (known PD-L1 status with prior testing by immunohistochemistry and a corresponding combined positive score (CPS))
Have known PD-L1 status with prior testing by immunohistochemistry and a corresponding combined positive score (CPS)
Required: CLDN18 2-positive (CLDN18.2-positive tumor expression)
Must have CLDN18.2-positive tumor expression
Disease stage
Required: Stage III, IV
locally advanced, unresectable or metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CLDN18.2-targeted therapy
Prior exposure to CLDN18.2 -targeted therapy
Cannot have received: 4-1BB agonist
Prior exposure to 4-1BB agonists
Cannot have received: anti-PD-1 therapy
Prior treatment with anti-PD-1 or PD-L1 agent
Cannot have received: anti-PD-L1 therapy
Prior treatment with anti-PD-1 or PD-L1 agent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stern Center for Cancer Clinical Trials and Research · Orange, California
- UCHealth Cancer Care - Anschutz Medical Campus · Aurora, Colorado
- Mass General Hospital · Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
- NYU Langone · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04900818 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CLDN18.2-targeted therapy, 4-1BB agonist, anti-PD-1 therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require CLDN18?
Yes, CLDN18 2-positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify